Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 May 1.

Published in final edited form as: Epidemiology. 2014 May;25(3):406–417. doi: 10.1097/EDE.0000000000000041

Figures 4a and b — Inverse probability weighted Kaplan-Meier curves for the time to myocardial infarction event among HIV-positive persons (identified by ICD-9 code and antiretroviral use in administrative claim) initiating protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTI) A. atazanavir alone or in combination with ritonavir compared with non-nucleoside reverse transcriptase inhibitors (efavirenz or nevirapine) B. lopinavir-ritonavir compared with non-nucleoside reverse transcriptase inhibitors (efavirenz or nevirapine). Note: axes focused on 90% to 100% surviving.

Figures 4a and b — Inverse probability weighted Kaplan-Meier curves for the time to myocardial infarction event among HIV-positive persons (identified by ICD-9 code and antiretroviral use in administrative claim) initiating protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTI) A. atazanavir alone or in combination with ritonavir compared with non-nucleoside reverse transcriptase inhibitors (efavirenz or nevirapine) B. lopinavir-ritonavir compared with non-nucleoside reverse transcriptase inhibitors (efavirenz or nevirapine). Note: axes focused on 90% to 100% surviving.